Justin B. Klee - Mar 6, 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Co-Chief Executive Officer, Director
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Mar 6, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/10/2025, 08:30 PM
Previous filing: Mar 5, 2025
Next filing: Apr 2, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Award	$0	+180K	+5.63%	$0.00	3.38M	Mar 6, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Award	$0	+270K		$0.00	270K	Mar 6, 2025	Common Stock	270K	$3.61	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2	25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.